Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURE-02 perioperative pembrolizumab + sacituzumab govitecan in muscle-invasive bladder cancer
2024-514569-20-00Phase 2Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and sacituzumab govitecan in muscle-invasive bladder carcinoma (MIBC) and transitional cell carcinoma of the bladder (TCC), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: clinical complete response rate. Planned start Oct 2024; status: authorised.
02
Drugs
pembrolizumabsacituzumab govitecan
03
Conditions
muscle-invasive bladder carcinoma (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2024-514569-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514569-20-00.